+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Premature Ejaculation Treatment Market 2024-2028

  • PDF Icon

    Report

  • 167 Pages
  • October 2023
  • Region: Global
  • TechNavio
  • ID: 5309558
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The premature ejaculation treatment market is forecasted to grow by USD 1459.85 mn during 2023-2028, accelerating at a CAGR of 8.78% during the forecast period. The report on the premature ejaculation treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high efficacy of off-label premature ejaculation drugs, increasing demand for topical drug therapies for premature ejaculation treatment, and growing risk factors causing premature ejaculation.

The premature ejaculation treatment market is segmented as below:

By Route Of Administration

  • Oral
  • Topical

By Drug Class

  • SSRIs
  • PDE5 inhibitors
  • Amide anesthetics
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the advent of nanotechnology in premature ejaculation treatment drugs as one of the prime reasons driving the premature ejaculation treatment market growth during the next few years. Also, increasing research and development related to premature ejaculation treatments and emergence of novel devices for premature ejaculation treatments will lead to sizable demand in the market.

The report on the premature ejaculation treatment market covers the following areas:

  • Premature ejaculation treatment market sizing
  • Premature ejaculation treatment market forecast
  • Premature ejaculation treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premature ejaculation treatment market vendors that include A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical plc, GlaxoSmithKline Plc, Johnson and Johnson, LloydsPharmacy, Morari Inc., NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical, Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt. Ltd., Tabuk Pharmaceuticals, Veru Inc., and VIVUS LLC. Also, the premature ejaculation treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global premature ejaculation treatment market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global premature ejaculation treatment market 2018 - 2022 ($ million)
4.2 Route of Administration Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
4.3 Drug Class Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration
6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Oral - Market size and forecast 2023-2028
Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Topical - Market size and forecast 2023-2028
Exhibit 38: Chart on Topical - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Topical - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Route of Administration
Exhibit 42: Market opportunity by Route of Administration ($ million)
Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Drug Class
7.1 Market segments
Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)
7.2 Comparison by Drug Class
Exhibit 46: Chart on Comparison by Drug Class
Exhibit 47: Data Table on Comparison by Drug Class
7.3 SSRIs - Market size and forecast 2023-2028
Exhibit 48: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)
7.4 PDE5 inhibitors - Market size and forecast 2023-2028
Exhibit 52: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
7.5 Amide anesthetics - Market size and forecast 2023-2028
Exhibit 56: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)
7.6 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Drug Class
Exhibit 64: Market opportunity by Drug Class ($ million)
Exhibit 65: Data Table on Market opportunity by Drug Class ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Italy - Market size and forecast 2023-2028
Exhibit 91: Chart on Italy - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Italy - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Italy - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Italy - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 India - Market size and forecast 2023-2028
Exhibit 103: Chart on India - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on India - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on India - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 A. Menarini Industrie Farmaceutiche Riunite Srl
Exhibit 115: A. Menarini Industrie Farmaceutiche Riunite Srl - Overview
Exhibit 116: A. Menarini Industrie Farmaceutiche Riunite Srl - Product/Service
Exhibit 117: A. Menarini Industrie Farmaceutiche Riunite Srl - Key offerings
12.4 Absorption Pharmaceuticals LLC
Exhibit 118: Absorption Pharmaceuticals LLC - Overview
Exhibit 119: Absorption Pharmaceuticals LLC - Product/Service
Exhibit 120: Absorption Pharmaceuticals LLC - Key offerings
12.5 Alembic Pharmaceuticals Ltd.
Exhibit 121: Alembic Pharmaceuticals Ltd. - Overview
Exhibit 122: Alembic Pharmaceuticals Ltd. - Product/Service
Exhibit 123: Alembic Pharmaceuticals Ltd. - Key offerings
12.6 Amneal Pharmaceuticals Inc.
Exhibit 124: Amneal Pharmaceuticals Inc. - Overview
Exhibit 125: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 126: Amneal Pharmaceuticals Inc. - Key news
Exhibit 127: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 128: Amneal Pharmaceuticals Inc. - Segment focus
12.7 Aytu BioPharma Inc.
Exhibit 129: Aytu BioPharma Inc. - Overview
Exhibit 130: Aytu BioPharma Inc. - Product/Service
Exhibit 131: Aytu BioPharma Inc. - Key offerings
12.8 Bayer AG
Exhibit 132: Bayer AG - Overview
Exhibit 133: Bayer AG - Business segments
Exhibit 134: Bayer AG - Key news
Exhibit 135: Bayer AG - Key offerings
Exhibit 136: Bayer AG - Segment focus
12.9 Eli Lilly and Co.
Exhibit 137: Eli Lilly and Co. - Overview
Exhibit 138: Eli Lilly and Co. - Product/Service
Exhibit 139: Eli Lilly and Co. - Key news
Exhibit 140: Eli Lilly and Co. - Key offerings
12.10 Futura Medical plc
Exhibit 141: Futura Medical plc - Overview
Exhibit 142: Futura Medical plc - Product/Service
Exhibit 143: Futura Medical plc - Key offerings
12.11 GlaxoSmithKline Plc
Exhibit 144: GlaxoSmithKline Plc - Overview
Exhibit 145: GlaxoSmithKline Plc - Business segments
Exhibit 146: GlaxoSmithKline Plc - Key news
Exhibit 147: GlaxoSmithKline Plc - Key offerings
Exhibit 148: GlaxoSmithKline Plc - Segment focus
12.12 Johnson and Johnson
Exhibit 149: Johnson and Johnson - Overview
Exhibit 150: Johnson and Johnson - Business segments
Exhibit 151: Johnson and Johnson - Key news
Exhibit 152: Johnson and Johnson - Key offerings
Exhibit 153: Johnson and Johnson - Segment focus
12.13 LloydsPharmacy
Exhibit 154: LloydsPharmacy - Overview
Exhibit 155: LloydsPharmacy - Product/Service
Exhibit 156: LloydsPharmacy - Key offerings
12.14 NeuroHealing Pharmaceuticals Inc.
Exhibit 157: NeuroHealing Pharmaceuticals Inc. - Overview
Exhibit 158: NeuroHealing Pharmaceuticals Inc. - Product/Service
Exhibit 159: NeuroHealing Pharmaceuticals Inc. - Key offerings
12.15 Pfizer Inc.
Exhibit 160: Pfizer Inc. - Overview
Exhibit 161: Pfizer Inc. - Product/Service
Exhibit 162: Pfizer Inc. - Key news
Exhibit 163: Pfizer Inc. - Key offerings
12.16 Plethora Solutions Ltd.
Exhibit 164: Plethora Solutions Ltd. - Overview
Exhibit 165: Plethora Solutions Ltd. - Product/Service
Exhibit 166: Plethora Solutions Ltd. - Key offerings
12.17 Veru Inc.
Exhibit 167: Veru Inc. - Overview
Exhibit 168: Veru Inc. - Business segments
Exhibit 169: Veru Inc. - Key offerings
Exhibit 170: Veru Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 171: Inclusions checklist
Exhibit 172: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 173: Currency conversion rates for US$
13.4 Research methodology
Exhibit 174: Research methodology
Exhibit 175: Validation techniques employed for market sizing
Exhibit 176: Information sources
13.5 List of abbreviations
Exhibit 177: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global premature ejaculation treatment market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits 31: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Route of Administration
Exhibits 33: Data Table on Comparison by Route of Administration
Exhibits 34: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Topical - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Topical - Year-over-year growth 2023-2028 (%)
Exhibits 42: Market opportunity by Route of Administration ($ million)
Exhibits 43: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits 44: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits 45: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits 46: Chart on Comparison by Drug Class
Exhibits 47: Data Table on Comparison by Drug Class
Exhibits 48: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibits 49: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibits 51: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibits 52: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 61: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 64: Market opportunity by Drug Class ($ million)
Exhibits 65: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 69: Chart on Geographic comparison
Exhibits 70: Data Table on Geographic comparison
Exhibits 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Italy - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on Italy - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on Italy - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Italy - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on India - Market size and forecast 2023-2028 ($ million)
Exhibits 104: Data Table on India - Market size and forecast 2023-2028 ($ million)
Exhibits 105: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on India - Year-over-year growth 2023-2028 (%)
Exhibits 107: Market opportunity By Geographical Landscape ($ million)
Exhibits 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 109: Impact of drivers and challenges in 2023 and 2028
Exhibits 110: Overview on Criticality of inputs and Factors of differentiation
Exhibits 111: Overview on factors of disruption
Exhibits 112: Impact of key risks on business
Exhibits 113: Vendors covered
Exhibits 114: Matrix on vendor position and classification
Exhibits 115: A. Menarini Industrie Farmaceutiche Riunite Srl - Overview
Exhibits 116: A. Menarini Industrie Farmaceutiche Riunite Srl - Product/Service
Exhibits 117: A. Menarini Industrie Farmaceutiche Riunite Srl - Key offerings
Exhibits 118: Absorption Pharmaceuticals LLC - Overview
Exhibits 119: Absorption Pharmaceuticals LLC - Product/Service
Exhibits 120: Absorption Pharmaceuticals LLC - Key offerings
Exhibits 121: Alembic Pharmaceuticals Ltd. - Overview
Exhibits 122: Alembic Pharmaceuticals Ltd. - Product/Service
Exhibits 123: Alembic Pharmaceuticals Ltd. - Key offerings
Exhibits 124: Amneal Pharmaceuticals Inc. - Overview
Exhibits 125: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 126: Amneal Pharmaceuticals Inc. - Key news
Exhibits 127: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 128: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 129: Aytu BioPharma Inc. - Overview
Exhibits 130: Aytu BioPharma Inc. - Product/Service
Exhibits 131: Aytu BioPharma Inc. - Key offerings
Exhibits 132: Bayer AG - Overview
Exhibits 133: Bayer AG - Business segments
Exhibits 134: Bayer AG - Key news
Exhibits 135: Bayer AG - Key offerings
Exhibits 136: Bayer AG - Segment focus
Exhibits 137: Eli Lilly and Co. - Overview
Exhibits 138: Eli Lilly and Co. - Product/Service
Exhibits 139: Eli Lilly and Co. - Key news
Exhibits 140: Eli Lilly and Co. - Key offerings
Exhibits 141: Futura Medical plc - Overview
Exhibits 142: Futura Medical plc - Product/Service
Exhibits 143: Futura Medical plc - Key offerings
Exhibits 144: GlaxoSmithKline Plc - Overview
Exhibits 145: GlaxoSmithKline Plc - Business segments
Exhibits 146: GlaxoSmithKline Plc - Key news
Exhibits 147: GlaxoSmithKline Plc - Key offerings
Exhibits 148: GlaxoSmithKline Plc - Segment focus
Exhibits 149: Johnson and Johnson - Overview
Exhibits 150: Johnson and Johnson - Business segments
Exhibits 151: Johnson and Johnson - Key news
Exhibits 152: Johnson and Johnson - Key offerings
Exhibits 153: Johnson and Johnson - Segment focus
Exhibits 154: LloydsPharmacy - Overview
Exhibits 155: LloydsPharmacy - Product/Service
Exhibits 156: LloydsPharmacy - Key offerings
Exhibits 157: NeuroHealing Pharmaceuticals Inc. - Overview
Exhibits 158: NeuroHealing Pharmaceuticals Inc. - Product/Service
Exhibits 159: NeuroHealing Pharmaceuticals Inc. - Key offerings
Exhibits 160: Pfizer Inc. - Overview
Exhibits 161: Pfizer Inc. - Product/Service
Exhibits 162: Pfizer Inc. - Key news
Exhibits 163: Pfizer Inc. - Key offerings
Exhibits 164: Plethora Solutions Ltd. - Overview
Exhibits 165: Plethora Solutions Ltd. - Product/Service
Exhibits 166: Plethora Solutions Ltd. - Key offerings
Exhibits 167: Veru Inc. - Overview
Exhibits 168: Veru Inc. - Business segments
Exhibits 169: Veru Inc. - Key offerings
Exhibits 170: Veru Inc. - Segment focus
Exhibits 171: Inclusions checklist
Exhibits 172: Exclusions checklist
Exhibits 173: Currency conversion rates for US$
Exhibits 174: Research methodology
Exhibits 175: Validation techniques employed for market sizing
Exhibits 176: Information sources
Exhibits 177: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global premature ejaculation treatment market: A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical plc, GlaxoSmithKline Plc, Johnson and Johnson, LloydsPharmacy, Morari Inc., NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical, Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt. Ltd., Tabuk Pharmaceuticals, Veru Inc., and VIVUS LLC.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is advent of nanotechnology in premature ejaculation treatment drugs.'

According to the report, one of the major drivers for this market is the high efficacy of off-label premature ejaculation drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Absorption Pharmaceuticals LLC
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Aytu BioPharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Futura Medical plc
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • LloydsPharmacy
  • Morari Inc.
  • NeuroHealing Pharmaceuticals Inc.
  • Niksan Pharmaceutical
  • Pfizer Inc.
  • Plethora Solutions Ltd.
  • Prinston Pharmaceutical Inc.
  • Ralington Pharma LLP
  • Sunrise Remedies Pvt. Ltd.
  • Tabuk Pharmaceuticals
  • Veru Inc.
  • VIVUS LLC